l e t t e r S PIK3CA gain-of-function mutations are a common oncogenic event in human malignancy [1] [2] [3] [4] , making phosphatidylinositol 3-kinase (PI3K) a target for cancer therapy. Despite the promise of targeted therapy, resistance often develops, leading to treatment failure. To elucidate mechanisms of resistance to PI3K-targeted therapy, we constructed a mouse model of breast cancer conditionally expressing human PIK3CA H1047R . Notably, most PIK3CA H1047R -driven mammary tumors recurred after PIK3CA H1047R inactivation. Genomic analyses of recurrent tumors revealed multiple lesions, including focal amplification of Met or Myc (also known as c-Met and c-Myc, respectively). Whereas Met amplification led to tumor survival dependent on activation of endogenous PI3K, tumors with Myc amplification became independent of the PI3K pathway. Functional analyses showed that Myc contributed to oncogene independence and resistance to PI3K inhibition. Notably, PIK3CA mutations and c-MYC elevation co-occur in a substantial fraction of human breast tumors. Together, these data suggest that c-MYC elevation represents a potential mechanism by which tumors develop resistance to current PI3K-targeted therapies.
More than 25% of breast cancers harbor somatic mutations in the PIK3CA-encoded p110α catalytic subunit of PI3K [1] [2] [3] [4] . These mutations usually occur in the helical region (E545K and E542K) or the kinase domain (H1047R) of p110α; H1047R is the most common mutation (>50% of cases). Several experimental models have demonstrated that these tumor-associated PIK3CA mutations lead to constitutive p110α activation and oncogenic transformation [5] [6] [7] [8] [9] , making the PIK3CA oncogene a target for cancer therapy.
To study the effects of mutational activation of PI3K on breast tumorigenesis in vivo and to identify potential mechanisms of resistance to PI3K inhibition, we generated a transgenic mouse line expressing human PIK3CA H1047R in which transgene expression is under the control of a tetracycline-inducible promoter (TetO). PIK3CA H1047R expression is coupled with a luciferase reporter allowing transgene expression to be followed in vivo (Fig. 1a) . To drive mammary-specific expression of PIK3CA H1047R , we crossed two TetO-PIK3CA H1047R founders (HR-2239 and HR-2251) to a previously described MMTV-rtTA (MTB) line 10 . The resulting bitransgenic MTB/TetO-PIK3CA H1047R mice were designated iPIK3CA H1047R . Quantitative RT-PCR analyses of mammary tissues isolated from bitransgenic females showed that doxycycline treatment led to a substantial increase in PIK3CA H1047R expression and luciferase reporter activity, whereas endogenous mouse Pik3ca expression remained unaffected ( Supplementary Fig. 1a,b) . As mice derived from both iPIK3CA H1047R founder lines showed comparable mammary glandspecific and doxycycline-dependent transgene expression, we used the MTB/HR-2239 line for all subsequent experiments.
To determine whether expression of PIK3CA H1047R can initiate transformation of mammary epithelium, we analyzed mammary glands isolated from iPIK3CA H1047R females treated with doxycycline for 4 weeks. Histological examination showed increased mammary ductal side-branching and enlarged focal nodular structures filled with hyperproliferative cells characteristic of early neoplastic lesions ( Supplementary Fig. 2a,b) . Immunohistochemical analyses showed strong phospho-AKT (p-AKT) signals in proliferating epithelial cells in the mammary glands of doxycycline-treated mice ( Supplementary  Fig. 2c ), indicating activation of PI3K signaling in response to the induction of PIK3CA H1047R . Consistent with the phenotype noted above, chronic doxycycline induction of the PIK3CA H1047R transgene in bitransgenic mice led to the development of mammary tumors with 95% penetrance and a mean latency of 7 months Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms (Fig. 1b) . These primary tumors had heterogeneous pathological phenotypes, including adenocarcinomas and adenosquamous carcinomas ( Fig. 1c and Supplementary Table 1) . In contrast, we observed no tumors in any of the control groups over the same time period (Fig. 1b) . Thus, sustained induction of oncogenic PIK3CA expression leads to mammary tumor formation.
To examine whether established tumors required continued PIK3CA H1047R expression to maintain their malignant state, we withdrew doxycycline from a cohort of tumor-bearing mice. All tumors regressed during the first week after doxycycline removal. We confirmed the suppression of PIK3CA H1047R expression after doxycycline withdrawal by RT-PCR in primary tumors ( Supplementary  Fig. 3 ). Immunohistochemical analyses showed markedly lower abundance of both p-Akt and phospho-S6 ribosomal protein (p-S6RP) in tumors from which doxycycline was withdrawn as compared with those maintained on doxycycline (Fig. 1d) . Moreover, although we detected a robust Ki67 signal in tumors maintained on doxycycline, there were significantly fewer proliferating cells after doxycycline withdrawal (Fig. 1e) . Conversely, whereas we detected only a few apoptotic cells in tumors on doxycycline, we observed substantially more TUNEL-positive cells in tumors after doxycycline removal (Fig. 1e) . These data indicate that reduced cellular l e t t e r S proliferation and increased apoptosis are responsible for the initial phase of tumor regression after downregulation of oncogenic PIK3CA.
To determine whether the continued inactivation of oncogenic p110α H1047R led to sustained regression of mammary carcinomas initiated by the expression of PIK3CA H1047R , we followed a large cohort of tumors after doxycycline withdrawal for up to 6 months. We found that one-third of tumors (45 of 135, 33%) rapidly and completely regressed to a nonpalpable state within 1-2 months after doxycycline withdrawal with no regrowth (Fig. 2a and Supplementary Fig. 4a ), indicating that these tumors remained dependent on p110α H1047R for their maintenance. Although a small fraction of tumors (4 of 135, 3%) regressed partially and did not resume growth after doxycycline removal, about two-thirds of tumors (86 of 135, 64%) partially regressed but then resumed growth without doxycycline ( Fig. 2a and  Supplementary Fig. 4b) . We confirmed that all recurrent tumors showed sustained downregulation of the PIK3CA H1047R transgene and its protein product (Fig. 2b) . Thus, PIK3CA H1047R -initiated mammary tumors frequently did not regress completely upon PIK3CA H1047R inactivation and recurred in a PIK3CA H1047R -independent manner.
We next examined whether the PI3K pathway remained active in recurrent tumors, thus compensating for the loss of PIK3CA H1047R expression. Western blot analyses of six paired primary and recurrent tumors showed that, although the phosphorylation levels of both AKT and S6RP were robust in all six primary tumors maintained on doxycycline, these signals were maintained in three recurrent tumors but were substantially lower in the other three (Fig. 2b) . We then transplanted these six recurrent tumors into the mammary fat pads of athymic mice, and treated the tumor-bearing recipients with GDC-0941, a pan-Class I PI3K inhibitor currently in clinical trials 11, 12 . Three recurrent tumors (RCT-D782, RCT-E565 and RCT-E302), all of which retained high abundance of both p-AKT and p-S6RP, were sensitive to GDC-0941 treatment (Fig. 2c) . In contrast, the three recurrent tumors (RCT-E473, RCT-D419 and RCT-C658), which showed lower p-AKT and p-S6RP abundance, were resistant to GDC-0941 (Fig. 2c) . These data suggest that some recurrent tumors escaped addiction to the oncogenic PIK3CA but remained dependent on the PI3K pathway, whereas others acquired the ability to grow independently of both the PIK3CA oncogene and the PI3K pathway.
To search for genomic aberrations associated with this recurrence, we carried out mouse single nucleotide polymorphism (SNP) array analyses of six recurrent tumors. A GDC-0941-sensitive tumor, RCT-E565, had a narrow amplification region encompassing Met (Fig. 3a) and also harbored a single-copy loss of the tumor suppressor gene Cdkn2a (Supplementary Fig. 5a ). Notably, two of three tumors that were resistant to GDC-0941 had a common amplification on chromosome 15 spanning 1.48 megabases (chromosome 15:61,271,320-62,750,432), which contains the coding sequence for a single gene, Myc (Fig. 3b b a l e t t e r S nature medicine VOLUME 17 | NUMBER 9 | SEPTEMBER 2011
and Supplementary Fig. 6 ). In addition to Myc amplification, RCT-C658 also carried an amplification encompassing the Mdm2 oncogene (Supplementary Fig. 5b ). Further analyses of c-Met, c-Myc and Mdm2 in a large collection of recurrent tumors showed that these oncogenes were upregulated in various fractions of recurrent tumors (Supplementary Figs. 7-12 and Supplementary Table 2 ). These data demonstrate that several of the most common gain-or loss-of-function genetic events in human cancers were recapitulated in this mouse tumor model. Because c-Met is a receptor tyrosine kinase that activates the PI3K pathway via ERBB3 and GAB1 (refs. 13,14), we tested whether Met amplification contributes to greater PI3K activity and tumor growth in the absence of PIK3CA H1047R expression. We confirmed that the RCT-E565 tumor, but not its parental primary tumor PMT-E565, had elevated c-Met mRNA and protein expression ( Supplementary  Fig. 13 ). We then treated mice bearing RCT-E565 tumor transplants with PF02341066, a c-Met inhibitor currently in clinical development 15 . PF02341066 abrogated both p-Akt and p-S6RP signals as well as tumor growth (Fig. 3c,d) . These results suggest that c-Met elevation is a mechanism underlying the growth of recurrent tumors that have escaped oncogenic PIK3CA addiction but remain dependent on the PI3K pathway.
Because two of three GDC-0941-insensitive recurrent tumors featured Myc amplification (Fig. 3b) and overexpression (Supplementary  Fig. 14) , and as c-Myc functions downstream of the PI3K pathway 16 , we hypothesized that c-Myc elevation might contribute to the recurrence of tumors that were resistant to PI3K inhibition. Further analyses of c-Myc for DNA copy number and both mRNA and protein expression in a large cohort of recurrent tumors ( Supplementary  Figs. 7-10) showed that c-Myc elevation frequently occurs in recurrent tumors after sustained PIK3CA H1047R inactivation. To test whether c-Myc elevation contributes to tumor recurrence in a PI3K pathway-independent manner, we examined the effects of Myc knockdown by shRNAs (sh-Myc1 and sh-Myc2) on the growth of recurrent tumors transplanted in the mammary fat pads of immunodeficient mice. Knockdown of Myc led to markedly lower tumor incidence and longer time to tumor onset (Fig. 4a,b) . Conversely, enforced expression of c-Myc or c-MycT58A, a more stable version of c-Myc 17 , rendered otherwise PIK3CA H1047R -dependent tumors able to grow without doxycycline (Fig. 4c-e) . Moreover, these c-Myc-or c-MycT58A-expressing tumors were resistant to GDC-0941 treatment ( Fig. 4f and Supplementary Fig. 15 ). Together, these data suggest that c-Myc elevation renders tumors free of addiction to PIK3CA H1047R and provides resistance to PI3K inhibition.
In our model, PIK3CA H1047R -induced tumors have three potential outcomes in response to PI3K inhibition (Fig. 4g) . For tumors that escape oncogene addiction and recur, c-Myc elevation represents a potential resistance mechanism with respect to current PI3K-targeted therapies in clinical trials. To explore whether PIK3CA mutations and c-MYC elevation coexist in human breast cancer, we analyzed several breast cancer data sets containing both PIK3CA mutation status and MYC copy number or expression data [18] [19] [20] [21] . Among these cohorts, we found that substantial fractions of PIK3CA mutation-positive tumors have increased MYC copy numbers as well as mRNA and c-MYC protein levels 22, 23 ( Supplementary Fig. 16 and Supplementary  Table 3 ). Taken together, our findings suggest that aberrant elevation of c-MYC is a potential mechanism by which tumors develop resistance to PI3K inhibition, and thus combination therapies targeting both PI3K and c-MYC may be necessary to circumvent resistance to PI3K-targeted therapy. 
